Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06181656
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Pneumonia vaccine — BIOLOGICAL
    Given by SC

Study Details

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Key Dates

Start date
Feb 5, 2024
Status verified
May 2026
Primary completion
Jul 4, 2027
Completion
Jul 4, 2027

Study Design

Enrollment
80 participants (estimated)

Arms

  • Arm: Group 1
    30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
  • Arm: Group 2
    30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
  • Arm: Group 3
    20 Healthy Volunteers.

Primary Outcome Measure

Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination [ Time Frame: through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Steven H Lin, MD
[email protected]
713-563-8490

Find similar trials in Houston, TX

By condition
Esophageal cancer
By specialty
OncologyGI oncology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies